For US residents only.
RYDAPT is an oral prescription medicine used in combination with certain chemotherapy medicines to treat adults with newly diagnosed acute myeloid leukemia (AML) who have a defect in a gene called FLT3. Your doctor will perform a test to make sure RYDAPT is right for you. RYDAPT should not be used alone to induce remission in people with AML.
RYDAPT is also used to treat adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).
It is not known if RYDAPT is safe and effective in children.
RYDAPT is available by prescription only.
If you have any questions about how RYDAPT works or why this medicine has been prescribed for you, ask your doctor or pharmacist.
FLT3 mutation testing is performed by The Laboratory for Personalized Molecular Medicine, a subsidiary of Invivoscribe Technologies, Inc., which has gained FDA approval for its FLT3 test as a companion diagnostic for RYDAPT in newly diagnosed FLT3+ AML. Laboratory for Personalized Molecular Medicine® is a registered trademark of Invivoscribe Technologies, Inc.